Bionote
Public · 1 known investors
Korea-listed BioNote manufactures rapid human and animal diagnostic kits plus diagnostic raw materials such as antigens and antibodies.
Also known as A377740 · Bionote Inc · BioNote, Inc.
Investors · 1
Company profile
researched Aug 2026BioNote, Inc. is a South Korean company operating in the bio-contents field. Its activities span the manufacture and sale of rapid diagnostic kits for human use, diagnostic raw materials including antigens, antibody cell lines, standards and enzymes, and semi-finished products supplied to other manufacturers. For the animal health market, the company produces rapid immunochemical diagnostics, enzyme immune rebound protein products and immunochemical fluorescence diagnostics.
The business is reported in two principal segments, Life Science and Animal. Segment disclosures show Animal revenue of KRW 65.64B in 2023 and KRW 71.82B in 2024, with Life Science revenue of KRW 24.44B and KRW 30.96B in the same years; earlier periods were reported under a combined Diagnostic Kits / Equipment segment (KRW 622B in 2021). The company employs 298 people and is headquartered at 22 Samsung, Hwaseong-si (postal code 18449), Gyeonggi Province, South Korea.
Business model
BioNote manufactures and sells finished rapid diagnostic test kits for human and veterinary use, as well as upstream diagnostic inputs (antigens, antibody cell lines, standards, enzymes) and semi-finished products, generating revenue across its Life Science and Animal segments.
Product sales of diagnostic kits, diagnostic raw materials and semi-finished products, split between the Life Science and Animal segments.
Traction
Reported first-quarter provisional operating profit of KRW 6.3 billion, up 35.2% year over year, with net income up 925% in the same quarter. Annual segment revenue reached a combined KRW 102.78B across the Life Science and Animal segments in 2024, up from KRW 90.08B in 2023.
Latest developments
In May, the company reported a 925% jump in first-quarter net income and provisional quarterly operating profit of KRW 6.3 billion, up 35.2% year over year, with shares rising about 3% on the news. Hye-Im Cho was appointed to sales and marketing leadership and joined the board in March 2025.
▸Full profile — market position, go-to-market, geography, history
Market position
Classified in the diagnostic and testing substances manufacturing sector and listed on the Korea Stock Exchange with a market capitalization of roughly $348M; sector peers cited alongside it include Ultragenyx Pharmaceutical, Sarepta Therapeutics and DK Life Science.
Go-to-market
Human clinical diagnostics customers and the animal/veterinary diagnostics market, plus manufacturers purchasing diagnostic raw materials and semi-finished goods.
Geography
Headquartered in Hwaseong-si, South Korea, with sales split between the domestic market and overseas. Overseas revenue was KRW 89.59B (2022), KRW 54.74B (2023) and KRW 64.92B (2024) against South Korean revenue of KRW 390B, KRW 35.34B and KRW 37.86B in those years. The 2021 geographic breakdown reported sales in Asia (KRW 31.21B), Europe (KRW 44.78B), the Americas (KRW 10.58B), Africa (KRW 6.25B) and Oceania (KRW 673M) alongside South Korea (KRW 529B).
History
Byung-Ki Cho has served as chief executive officer since July 2020, and Guk-Myung Lee as chief financial officer since March 2021. Young-Sik Cho became chairman of the board in February 2023; other board members joined between 2018 and 2025. The shares trade in Korea under the code A377740.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 5
launches, deals, and filingsThe company reported a 925% year-over-year jump in first-quarter net income and provisional quarterly operating profit of KRW 6.3 billion, up 35.2% year over year; shares rose about 3%.
Young-Sik Cho, the company's largest shareholder with a 50.3% stake, became chairman on 28 February 2023.
Guk-Myung Lee took the role of Director of Finance/CFO on 31 March 2021.
Byung-Ki Cho has served as chief executive officer and a board member since 31 July 2020.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 2
primary sources listed
- BioNote, Inc.: Shareholders Board Members Managers and Company Profile | KR7377740006 | MarketScreenermarketscreener.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Bionote do?
- Korea-listed BioNote manufactures rapid human and animal diagnostic kits plus diagnostic raw materials such as antigens and antibodies.
- Who are Bionote's investors?
- Bionote's investors include Atinum Investment Co. Ltd..